CGVHD
Clinical trials for CGVHD explained in plain language.
Never miss a new study
Get alerted when new CGVHD trials appear
Sign up with your email to follow new studies for CGVHD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for stubborn Graft-Versus-Host disease: experimental drug combo enters early trial
Disease control Not yet recruitingThis early-phase study tests whether the drug sarilumab can safely help adults with chronic graft-versus-host disease (cGVHD) that did not improve with the standard drug belumosudil. Ten participants will receive sarilumab alone, and researchers will monitor side effects and drug…
Matched conditions: CGVHD
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New antibody cocktail targets stubborn liver disease after stem cell transplants
Disease control Not yet recruitingThis study tests a lab-made antibody called anti-CD25 rhMAb for people with chronic graft-versus-host disease (cGVHD) of the liver that hasn't improved with steroids. The antibody is given alongside standard immune-suppressing drugs. The trial will include 30 adults aged 16-65 wh…
Matched conditions: CGVHD
Phase: PHASE4 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to tame transplant complication
Disease control Not yet recruitingThis phase 2 trial tests a combination of two oral drugs, ruxolitinib and belumosudil, for chronic graft-versus-host disease (cGvHD) that hasn't improved with steroids. cGvHD is a serious condition where donor immune cells attack the patient's body after a stem cell transplant. T…
Matched conditions: CGVHD
Phase: PHASE2 • Sponsor: Dennis Kim • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug gecacitinib tested for tough transplant complication
Disease control Not yet recruitingThis study tests a drug called gecacitinib in 33 adults who have chronic graft-versus-host disease (cGVHD) after a stem cell transplant and whose condition hasn't improved with steroids. The goal is to find a safe dose and see if it helps control the disease. Participants take th…
Matched conditions: CGVHD
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Can a skin biopsy reveal how axatilimab fights scarring in chronic GVHD?
Knowledge-focused Not yet recruitingThis study investigates how axatilimab, an FDA-approved drug for chronic graft-versus-host disease (cGVHD), changes immune cells in the skin. Researchers will analyze skin and blood samples from 15 adults with skin cGVHD—10 starting axatilimab and 5 not receiving it—to understand…
Matched conditions: CGVHD
Sponsor: Northwestern University • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC